https://thepharmadata.com/lillys-tirzepatide-reduces-osa-severity-resolves-disease-in-51-5-of-participants/ 2024-06-22T04:43:45+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Lillys-Tirzepatide-Reduces-OSA-Severity-Resolves-Disease-in-51.5-of-Participants-1.webp https://thepharmadata.com/sanofi-and-biovac-enhance-polio-vaccine-manufacturing-in-africa/ 2024-06-20T12:12:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Sanofi-and-Biovac-Enhance-Polio-Vaccine-Manufacturing-in-Africa.webp https://thepharmadata.com/eu-approves-truqap-plus-faslodex-for-advanced-er-positive-breast-cancer-treatment/ 2024-06-20T12:08:18+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Treatment-3.webp https://thepharmadata.com/roche-unveils-advanced-test-for-easier-b-cell-lymphoma-diagnosis/ 2024-06-20T11:58:42+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Lymphoma-3.webp https://thepharmadata.com/fda-approves-skyrizi-for-ulcerative-colitis-expanding-abbvies-ibd-portfolio/ 2024-06-20T11:16:14+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Approves.webp https://thepharmadata.com/eli-lillys-open-letter-on-mounjaro-and-zepbound-practices/ 2024-06-20T11:07:35+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Letter.webp https://thepharmadata.com/actylis-announces-appointment-of-scott-thomson-as-chief-executive-officer/ 2024-06-19T11:29:55+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Actylis-Announces-Appointment-of-Scott-Thomson-as-Chief-Executive-Officer.webp https://thepharmadata.com/marinus-pharmaceuticals-releases-key-findings-from-iv-ganaxolone-phase-3-raise-trial-for-refractory-status-epilepticus/ 2024-06-19T11:25:27+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Pharmaceuticals-2.webp https://thepharmadata.com/takeda-reports-phase-3-findings-of-soticlestat-tak-935-in-patients-with-dravet-syndrome-and-lennox-gastaut-syndrome/ 2024-06-19T11:08:46+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Syndrome.webp https://thepharmadata.com/umc-utrecht-and-vectory-therapeutics-collaborate-in-als-biomarker-study/ 2024-06-19T11:05:52+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Therapeutics-1.webp https://thepharmadata.com/updated-results-shared-for-sanofis-blood-cancer-trial-sar443579-iph6101/ 2024-06-19T11:02:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Cancer-2.webp https://thepharmadata.com/celltrion-presents-positive-phase-iii-results-of-ct-p47-for-rheumatoid-arthritis-at-eular-2024/ 2024-06-19T10:54:34+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Phase-III-Results.webp https://thepharmadata.com/celltrion-unveils-promising-phase-iii-results-for-ct-p47-a-biosimilar-to-roactemra-in-ra-patients-at-eular-2024/ 2024-06-19T10:50:31+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Results.webp https://thepharmadata.com/genentechs-phase-iii-starglo-study-columvi-extends-survival-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/ 2024-06-19T10:29:22+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Lymphoma-2.webp https://thepharmadata.com/beigene-to-present-sequoia-study-data-on-brukinsa-and-venetoclax-in-high-risk-cll-sll-at-eha2024/ 2024-06-19T10:24:16+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/BeiGene-to-Present-SEQUOIA-Study-Data-on-BRUKINSA.webp https://thepharmadata.com/sparrow-pharma-shares-phase-2-trial-data-on-clofutriben-and-prednisolone-for-polymyalgia-rheumatica-at-eular-2024/ 2024-06-19T10:19:14+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Sparrow-Pharma-Shares-Phase-2-Trial-Data-on-Clofutriben-and-Prednisolone.webp https://thepharmadata.com/presentation-of-new-sequoia-study-findings-brukinsa-and-venetoclax-in-high-risk-first-line-cll-sll-at-eha2024/ 2024-06-15T07:01:58+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Presentation-of-New-SEQUOIA-Study-Findings-BRUKINSA%C2%AE-and-Venetoclax-in-High-Risk-First-Line-CLLSLL-at-EHA2024.webp https://thepharmadata.com/kirin-holdings-commences-tender-offer-to-make-fancl-a-wholly-owned-subsidiary/ 2024-06-15T06:51:19+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Kirin-Holdings-Commences-Tender-Offer-To-Make-FANCL-A-Wholly-Owned-Subsidiary-2.webp https://thepharmadata.com/enveda-biosciences-secures-55-million-to-boost-platform-development-and-propel-multiple-candidates-towards-clinical-trials/ 2024-06-15T06:35:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Clinical-2.webp https://thepharmadata.com/who-alarmed-by-worsening-health-emergency-in-west-bank/ 2024-06-15T06:04:44+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Emergency.webp https://thepharmadata.com/who-introduces-updated-guidelines-for-fiscal-policies-promoting-healthy-diets/ 2024-06-15T06:00:36+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Healthy-Diets.webp https://thepharmadata.com/who-issues-report-on-antibacterial-development-progress/ 2024-06-15T05:57:48+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/WHO-Issues-Report-on-Antibacterial-Development-Progress.webp https://thepharmadata.com/zimbabwe-achieves-who-maturity-level-3-in-medicine-regulation-joining-africas-elite-six/ 2024-06-15T05:54:21+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Zimbabwe-Achieves-WHO-Maturity-Level-3-in-Medicine-Regulation-Joining-Africas-Elite-Six.webp https://thepharmadata.com/takeda-to-secure-global-license-for-olverembatinib-from-ascentage-pharma/ 2024-06-15T05:21:26+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Takeda-to-Secure-Global-License-for-Olverembatinib-from-Ascentage-Pharma.webp https://thepharmadata.com/vertex-reveals-positive-long-term-casgevy-data-at-2024-eha-congress/ 2024-06-15T05:08:27+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Vertex-Reveals-Positive-Long-Term-CASGEVY%E2%84%A2-Data-at-2024-EHA-Congress.webp https://thepharmadata.com/fda-approves-augtyro-for-ntrk-positive-advanced-solid-tumors/ 2024-06-15T05:02:01+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/FDA-Approves-Augtyro%E2%84%A2-for-NTRK-Positive-Advanced-Solid-Tumors.webp https://thepharmadata.com/fda-approves-blincyto-for-cd19-positive-b-all-consolidation-phase/ 2024-06-15T04:52:39+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/FDA-Approves-BLINCYTO%C2%AE-for-CD19-Positive-B-ALL-Consolidation-Phase.webp https://thepharmadata.com/elrexfio-achieves-median-overall-survival-exceeding-two-years-in-relapsed-or-refractory-multiple-myeloma-patients/ 2024-06-15T04:48:19+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Patients.webp https://thepharmadata.com/farxiga-gains-fda-approval-for-treating-pediatric-type-2-diabetes-in-the-us/ 2024-06-15T04:28:38+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Farxiga-Gains-FDA-Approval-for-Treating-Pediatric-Type-2-Diabetes-in-the-US.webp https://thepharmadata.com/scientific-debate-on-defeating-aging-concludes-with-10000-prize-and-surprising-verdict-promising-new-investment-opportunities/ 2024-06-13T12:32:19+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Scientific-Debate-on-Defeating-Aging-Concludes-with-10000-Prize-and-Surprising-Verdict-Promising-New-Investment-Opportunities.webp https://thepharmadata.com/enhancing-clinical-trial-productivity-through-ai-insights-from-eclinical-solutions-at-citeline-roundtable-dia-and-beyond/ 2024-06-13T12:13:52+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Clinical.webp https://thepharmadata.com/cmi-media-group-utilizes-kerv-interactive-technology-for-introducing-video-attention-metrics-in-pharmaceutical-advertising/ 2024-06-13T11:45:13+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Pharmaceutical.webp https://thepharmadata.com/bay-area-research-logistics-opens-new-us-location-to-enhance-global-presence-and-customer-service/ 2024-06-13T11:41:22+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Bay-Area-Research-Logistics-Opens-New-US-Location-to-Enhance-Global-Presence-and-Customer-Service.webp https://thepharmadata.com/cranbury-pharmaceuticals-gains-fda-approval-for-generic-emflaza-oral-suspension-deflazacort-for-duchenne-muscular-dystrophy/ 2024-06-13T10:51:23+00:00 https://thepharmadata.com/new-thermo-scientific-heracell-incubators-propel-the-future-of-fully-automated-labs/ 2024-06-13T10:38:38+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/New-Thermo-Scientific-Heracell-Incubators-Propel-the-Future-of-Fully-Automated-Labs.webp https://thepharmadata.com/veteran-pharma-oncology-developer-krista-mckerracher-appointed-as-genialis-board-chairperson/ 2024-06-13T10:33:57+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Veteran-Pharma-Oncology-Developer-Krista-McKerracher-Appointed-as-Genialis-Board-Chairperson.webp https://thepharmadata.com/sibylla-biotech-and-md-anderson-forge-strategic-partnership-to-advance-small-molecule-protein-degrader-development/ 2024-06-13T10:29:27+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Sibylla-Biotech-and-MD-Anderson-Forge-Strategic-Partnership-to-Advance-Small-Molecule-Protein-Degrader-Development.webp https://thepharmadata.com/tagrisso-receives-us-priority-review-for-unresectable-stage-iii-egfr-mutated-lung-cancer/ 2024-06-11T11:34:44+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Tagrisso-Receives-US-Priority-Review-for-Unresectable-Stage-III-EGFR-Mutated-Lung-Cancer-1.webp https://thepharmadata.com/roches-four-in-one-test-for-covid-19-flu-and-rsv-gets-fda-eua/ 2024-06-11T11:29:05+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/COVID-19-1.webp https://thepharmadata.com/eu-approves-roches-alecensa-as-first-adjuvant-therapy-for-alk-early-stage-lung-cancer/ 2024-06-11T11:25:00+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/EU-Approves-Roches-Alecensa-as-First-Adjuvant-Therapy-for-ALK-Early-Stage-Lung-Cancer.webp https://thepharmadata.com/maia-biotechs-latest-advancements-yearly-success-and-breakthroughs-in-cancer-treatment/ 2024-06-08T07:00:09+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Cancer-1.webp https://thepharmadata.com/gerons-rytelo-approved-by-fda-for-lower-risk-mds-treatment/ 2024-06-08T06:46:03+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Gerons-RYTELO%E2%84%A2-Approved-by-FDA-for-Lower-Risk-MDS-Treatment.webp https://thepharmadata.com/fda-greenlights-arexvy-by-gsk-first-rsv-vaccine-for-high-risk-adults-50-59/ 2024-06-08T06:41:43+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Greenlights.webp https://thepharmadata.com/fda-clears-gsks-arexvy-for-adults-50-59-expanded-rsv-vaccine-use/ 2024-06-08T06:36:35+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/FDA-Clears-GSKs-AREXVY-for-Adults-50-59-Expanded-RSV-Vaccine-Use.webp https://thepharmadata.com/fda-approval-validates-maia-biotechnologys-telomere-targeting-therapy-using-a-telomerase-inhibitor/ 2024-06-08T06:18:18+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Approval.webp https://thepharmadata.com/majority-of-children-with-severe-sma-maintain-or-gain-mobility-with-genentechs-evrysdi-5-year-data/ 2024-06-08T06:07:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Mobility.webp https://thepharmadata.com/new-clinical-findings-unveiled-by-arcturus-therapeutics-at-the-47th-annual-european-cystic-fibrosis-conference/ 2024-06-08T06:00:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/New-Clinical-Findings-Unveiled-by-Arcturus-Therapeutics-at-the-47th-Annual-European-Cystic-Fibrosis-Conference.webp https://thepharmadata.com/2023-2030-global-dressings-market-analysis-key-players-revealed/ 2024-06-08T05:49:51+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/2023-2030-Global-Dressings-Market-Analysis-Key-Players-Revealed.webp https://thepharmadata.com/helix-unveils-clinico-genomic-datasets-covering-cardiovascular-metabolic-immunology-and-inflammation-disorders/ 2024-06-08T05:45:17+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Helix-Unveils-Clinico-Genomic-Datasets-Covering-Cardiovascular-Metabolic-Immunology-and-Inflammation-Disorders.webp https://thepharmadata.com/automated-liquid-handling-systems-market-2024-2029-ai-lab-complexity-miniaturization-trends/ 2024-06-08T05:32:36+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Lab.webp https://thepharmadata.com/urogen-pharma-announces-inducement-grants-in-accordance-with-nasdaq-listing-rule-5635c4/ 2024-06-08T05:16:54+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Announces.webp https://thepharmadata.com/bwxt-medical-submits-actinium-225-api-drug-master-file-to-fda/ 2024-06-08T05:13:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/BWXT-Medical-Submits-Actinium-225-API-Drug-Master-File-to-FDA.webp https://thepharmadata.com/vertex-showcases-trikafta-benefits-at-european-cystic-fibrosis-conference/ 2024-06-08T05:02:56+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Vertex-Showcases-TRIKAFTA%C2%AE-Benefits-at-European-Cystic-Fibrosis-Conference.webp https://thepharmadata.com/lillys-chief-financial-officer-anat-ashkenazi-to-step-down/ 2024-06-06T05:37:22+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Lillys-Chief-Financial-Officer-Anat-Ashkenazi-to-Step-Down.webp https://thepharmadata.com/being-diagnosed-with-lung-cancer-was-the-last-thing-i-expected/ 2024-06-06T05:01:55+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Being-Diagnosed-with-Lung-Cancer-Was-the-Last-Thing-I-Expected.webp https://thepharmadata.com/top-4-insights-from-johnson-johnsons-2023-health-for-humanity-report/ 2024-06-06T04:57:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Top-4-Insights-from-Johnson-Johnsons-2023-Health-for-Humanity-Report.webp https://thepharmadata.com/invite-friends-to-join-alle-allergan-aesthetics-loyalty-program-and-earn-50/ 2024-06-06T04:46:03+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Invite-Friends-to-Join-Alle-Allergan-Aesthetics-Loyalty-Program-and-Earn-50.webp https://thepharmadata.com/rinvoq-approved-for-kids-2-with-jia-and-psoriatic-arthritis/ 2024-06-06T04:40:15+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Approved.webp https://thepharmadata.com/abbvie-launches-phase-3-trial-for-multiple-myeloma-drug-abbv-383/ 2024-06-06T04:29:27+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Myeloma.webp https://thepharmadata.com/incyte-completes-acquisition-of-escient-pharmaceuticals/ 2024-06-01T07:21:18+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Incyte-Completes-Acquisition-Of-Escient-Pharmaceuticals.webp https://thepharmadata.com/wuxi-biologics-unveils-2023-esg-report-showcasing-robust-sustainability-initiatives/ 2024-06-01T06:16:36+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/WuXi-Biologics-Unveils-2023-ESG-Report-Showcasing-Robust-Sustainability-Initiatives.webp https://thepharmadata.com/barda-grants-qpex-biopharma-a-shionogi-group-entity-an-extra-10m-to-boost-antibiotic-portfolio-combatting-drug-resistant-infections/ 2024-06-01T06:12:17+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/BARDA-Grants-Qpex-Biopharma-a-Shionogi-Group-Entity-an-Extra-10M-to-Boost-Antibiotic-Portfolio-Combatting-Drug-Resistant-Infections.webp https://thepharmadata.com/ucbs-bimzelx%e2%96%bc-bimekizumab-320-mg-device-earns-favorable-chmp-opinion/ 2024-06-01T06:05:14+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/UCBs-BIMZELX%C2%AE%E2%96%BC-bimekizumab-320-mg-Device-Earns-Favorable-CHMP-Opinion.webp https://thepharmadata.com/labcorps-assortment-of-abstracts-on-precision-oncology-featured-at-2024-asco-annual-meeting/ 2024-06-01T06:00:05+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Labcorps-Assortment-of-Abstracts-on-Precision-Oncology-Featured-at-2024-ASCO-Annual-Meeting.webp https://thepharmadata.com/fda-recognizes-astellas-renewed-submission-of-biologics-license-application-for-zolbetuximab-and-establishes-revised-action-deadline/ 2024-06-01T05:54:48+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/FDA-Approves-Bristol-Myers-Squibbs-Breyanzi-for-RelapsedRefractory-Mantle-Cell-Lymphoma-CAR-T-Cell-Therapy.webp https://thepharmadata.com/biogens-qalsody-tofersen-approved-by-european-commission-for-rare-genetic-als-treatment/ 2024-06-01T05:40:56+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Biogens-QALSODY%C2%AE-tofersen-Approved-by-European-Commission-for-Rare-Genetic-ALS-Treatment.webp https://thepharmadata.com/takeda-gets-favorable-chmp-opinion-for-radamts13-in-cttp/ 2024-06-01T05:33:30+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Takeda-Gets-Favorable-CHMP-Opinion-for-rADAMTS13-in-cTTP.webp https://thepharmadata.com/pfizers-lorbrena-crown-trial-reveals-prolonged-progression-free-survival-for-most-alk-positive-advanced-lung-cancer-patients-over-five-years/ 2024-06-01T05:21:16+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Pfizers-LORBRENA%C2%AE-CROWN-Trial-Reveals-Prolonged-Progression-Free-Survival-for-Most-ALK-Positive-Advanced-Lung-Cancer-Patients-Over-Five-Years.webp https://thepharmadata.com/fda-approves-bristol-myers-squibbs-breyanzi-for-relapsed-refractory-mantle-cell-lymphoma-car-t-cell-therapy/ 2024-06-01T05:15:39+00:00 https://thepharmadata.com/sanofi-unveils-2024-global-employee-stock-purchase-plan/ 2024-06-01T05:00:28+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Sanofi-Unveils-2024-Global-Employee-Stock-Purchase-Plan.webp https://thepharmadata.com/sanofi-update-on-zantac-litigation/ 2024-06-01T04:53:38+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Sanofi-update-on-Zantac-litigation.webp https://thepharmadata.com/abbvie-gets-chmp-nod-for-skyrizi-to-treat-severe-ulcerative-colitis/ 2024-06-01T04:38:16+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/AbbVie-Gets-CHMP-Nod-for-SKYRIZI%C2%AE-to-Treat-Severe-Ulcerative-Colitis.webp https://thepharmadata.com/dedicated-scientist-committed-to-advancing-eye-health-innovations-globally/ 2024-06-01T04:28:09+00:00 https://thepharmadata.com/wp-content/uploads/2024/06/Dedicated-Scientist-Committed-to-Advancing-Eye-Health-Innovations-Globally.webp https://thepharmadata.com/igc-pharma-begins-patient-enrollment-for-phase-2-trial-of-igc-ad1-at-neurostudies/ 2024-05-29T05:36:09+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/IGC-Pharma-Begins-Patient-Enrollment-for-Phase-2-Trial-of-IGC-AD1-at-Neurostudies.webp https://thepharmadata.com/dr-michael-donovan-to-lead-personalized-cancer-therapy-at-cellworks-new-clia-lab/ 2024-05-29T05:29:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Dr.-Michael-Donovan-to-Lead-Personalized-Cancer-Therapy-at-Cellworks-New-CLIA-Lab.webp https://thepharmadata.com/be-biopharma-receives-fda-clearance-for-be-101-ind-application-in-hemophilia-b/ 2024-05-29T05:17:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Be-Biopharma-Receives-FDA-Clearance-for-BE-101-IND-Application-in-Hemophilia-B.webp https://thepharmadata.com/coya-therapeutics-added-to-msci-usa-micro-cap-index/ 2024-05-29T05:06:12+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Coya-Therapeutics-Added-to-MSCI-USA-Micro-Cap-Index.webp https://thepharmadata.com/medsir-and-debiopharm-collaborate-on-advanced-breast-cancer-treatment/ 2024-05-29T05:01:45+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/MEDSIR-and-Debiopharm-Collaborate-on-Advanced-Breast-Cancer-Treatment-1.webp https://thepharmadata.com/sarclisa-receives-fda-priority-review-for-treating-newly-diagnosed-multiple-myeloma/ 2024-05-28T04:31:04+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Sarclisa-Receives-FDA-Priority-Review-for-Treating-Newly-Diagnosed-Multiple-Myeloma.webp https://thepharmadata.com/coming-full-circle-from-curiosity-about-life-on-earth-to-transformative-therapies-at-novartis/ 2024-05-28T04:24:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Coming-Full-Circle-From-Curiosity-About-Life-on-Earth-to-Transformative-Therapies-at-Novartis.webp https://thepharmadata.com/datopotamab-deruxtecan-improves-survival-in-advanced-non-squamous-nsclc-tropion-lung01-phase-iii-results/ 2024-05-28T04:18:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Datopotamab-Deruxtecan-Improves-Survival-in-Advanced-Non-Squamous-NSCLC-TROPION-Lung01-Phase-III-Results.webp https://thepharmadata.com/updates-to-roches-expanded-corporate-executive-committee/ 2024-05-28T04:04:36+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Updates-to-Roches-Expanded-Corporate-Executive-Committee.webp https://thepharmadata.com/bridgebio-pharma-to-share-further-insights-on-acoramidis-study-for-transthyretin-amyloid-cardiomyopathy-at-2024-isa-meeting/ 2024-05-25T07:38:10+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Meeting-2.webp https://thepharmadata.com/latest-findings-wainua-eplontersen-study-results-at-2024-isa/ 2024-05-25T07:13:57+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Latest-Findings-WAINUA-eplontersen-Study-Results-at-2024-ISA.webp https://thepharmadata.com/who-member-states-to-share-historic-ihr-pandemic-agreement-outcomes-at-world-health-assembly/ 2024-05-25T07:08:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Agreement.webp https://thepharmadata.com/arrival-of-r21-malaria-vaccine-in-central-african-republic-advancing-child-survival/ 2024-05-25T07:04:42+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Arrival-of-R21-Malaria-Vaccine-in-Central-African-Republic-Advancing-Child-Survival.webp https://thepharmadata.com/covid-19-wipes-out-decade-of-global-life-expectancy-gains/ 2024-05-25T06:58:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/COVID-19-Wipes-Out-Decade-of-Global-Life-Expectancy-Gains.webp https://thepharmadata.com/whos-framework-to-improve-mpox-prevention-and-control/ 2024-05-25T06:57:00+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/WHOs-Framework-to-Improve-MPOX-Prevention-and-Control.webp https://thepharmadata.com/legend-biotech-showcases-car-t-cell-therapy-leadership-for-multiple-myeloma-patients-at-asco-and-eha/ 2024-05-25T05:44:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Legend-Biotech-Showcases-CAR-T-Cell-Therapy-Leadership-for-Multiple-Myeloma-Patients-at-ASCO-and-EHA.webp https://thepharmadata.com/eisai-unveils-oncology-portfolio-and-pipeline-at-asco-2024/ 2024-05-25T05:30:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Eisai-Unveils-Oncology-Portfolio-and-Pipeline-at-ASCO-2024.webp https://thepharmadata.com/ucb-announces-publication-in-the-lancet-of-phase-3-bimekizumab%e2%96%bc-trials-for-moderate-to-severe-hidradenitis-suppurativa/ 2024-05-25T05:22:13+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/UCB-Announces-Publication-in-The-Lancet-of-Phase-3-Bimekizumab%E2%96%BC-Trials-for-Moderate-to-Severe-Hidradenitis-Suppurativa.webp https://thepharmadata.com/brukinsa-data-presented-at-asco-highlights-distinctive-clinical-efficacy-for-cll-and-sll-treatment/ 2024-05-25T05:15:46+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/BRUKINSA-Data-Presented-at-ASCO-Highlights-Distinctive-Clinical-Efficacy-for-CLL-and-SLL-Treatment.webp https://thepharmadata.com/empowering-women-in-clinical-trials-5-inspiring-quotes-to-drive-change/ 2024-05-25T04:52:53+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Empowering-Women-in-Clinical-Trials-5-Inspiring-Quotes-to-Drive-Change.webp https://thepharmadata.com/merck-to-present-latest-cancer-research-advancements-at-asco-2024/ 2024-05-25T04:32:16+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Merck-to-Present-Latest-Cancer-Research-Advancements-at-ASCO-2024.webp https://thepharmadata.com/lilly-invests-9b-in-indiana-site-to-boost-tirzepatide-and-pipeline-api-production/ 2024-05-25T04:23:00+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Lilly-Invests-9B-in-Indiana-Site-to-Boost-Tirzepatide-and-Pipeline-API-Production.webp https://thepharmadata.com/astellas-and-yaskawa-partner-to-forge-a-cutting-edge-cell-therapy-ecosystem-blending-pharmaceutical-and-robotics-expertise/ 2024-05-22T05:33:47+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Astellas-and-YASKAWA-Partner-to-Forge-a-Cutting-Edge-Cell-Therapy-Ecosystem-Blending-Pharmaceutical-and-Robotics-Expertise.webp https://thepharmadata.com/nature-communications-csl-arcturus-covid-19-vaccine-efficacy-data-published/ 2024-05-22T05:26:56+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Nature-Communications-CSL-Arcturus-COVID-19-Vaccine-Efficacy-Data-Published.webp https://thepharmadata.com/aetna-grants-400k-for-roanoke-va-residential-facility-helping-moms-with-substance-use-disorder/ 2024-05-22T05:17:32+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Aetna-Grants-400K-for-Roanoke-VA-Residential-Facility-Helping-Moms-with-Substance-Use-Disorder.webp https://thepharmadata.com/empowering-schizophrenia-community-live-your-possczible-campaign-with-bristol-myers-squibb-and-taye-diggs/ 2024-05-22T05:11:56+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Empowering-Schizophrenia-Community-Live-Your-PosSCZible-Campaign-with-Bristol-Myers-Squibb-and-Taye-Diggs.webp https://thepharmadata.com/live-your-possczible-campaign-bristol-myers-squibb-taye-diggs-and-schizophrenia-community-unite-to-empower-individuals-with-schizophrenia/ 2024-05-22T05:01:04+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Live-Your-PosSCZible-Campaign-Bristol-Myers-Squibb-Taye-Diggs-and-Schizophrenia-Community-Unite-to-Empower-Individuals-with-Schizophrenia.webp https://thepharmadata.com/astrazeneca-aims-for-80-billion-in-revenue-by-2030-with-continued-growth-beyond/ 2024-05-22T04:49:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AstraZeneca-Aims-for-80-Billion-in-Revenue-by-2030-with-Continued-Growth-Beyond.webp https://thepharmadata.com/astrazeneca-announces-1-5-billion-facility-for-antibody-drug-conjugates-adcs-manufacturing-in-singapore/ 2024-05-22T04:41:08+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AstraZeneca-Announces-1.5-Billion-Facility-for-Antibody-Drug-Conjugates-ADCs-Manufacturing-in-Singapore.webp https://thepharmadata.com/fda-grants-breakthrough-status-to-roches-inavolisib-for-advanced-hr-her2-breast-cancer/ 2024-05-22T04:36:49+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/FDA-Grants-Breakthrough-Status-to-Roches-Inavolisib-for-Advanced-HR-HER2-Breast-Cancer.webp https://thepharmadata.com/nurse-leads-clinical-trials-for-innovative-cancer-therapies/ 2024-05-22T04:30:38+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Nurse-Leads-Clinical-Trials-for-Innovative-Cancer-Therapies.webp https://thepharmadata.com/over-half-of-crohns-patients-achieve-remission-with-lillys-mirikizumab-at-one-year/ 2024-05-22T04:19:17+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Over-Half-of-Crohns-Patients-Achieve-Remission-with-Lillys-Mirikizumab-at-One-Year.webp https://thepharmadata.com/upneeq-clinches-2024-shape-skin-award-for-best-lift-in-the-professional-treatment-category/ 2024-05-18T06:26:35+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Upneeq%C2%AE-Clinches-2024-Shape-Skin-Award-for-Best-Lift-in-the-Professional-Treatment-Category.webp https://thepharmadata.com/bluebird-bio-investor-alert-class-action-lawsuit-deadline-approaching/ 2024-05-18T06:19:55+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Bluebird-Bio-Investor-Alert-Class-Action-Lawsuit-Deadline-Approaching.webp https://thepharmadata.com/guardant-health-discloses-inducement-awards-in-accordance-with-nasdaq-listing-rule-5635c4/ 2024-05-18T06:14:56+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Health.webp https://thepharmadata.com/brenmillers-project-pipeline-surges-to-49-projects-encompassing-over-500-million-potential-value-in-12-industries-across-13-countries/ 2024-05-18T06:11:30+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Brenmillers-Project-Pipeline-Surges-to-49-Projects-Encompassing-Over-500-Million-Potential-Value-in-12-Industries-Across-13-Countries.webp https://thepharmadata.com/maia-biotechnology-set-to-showcase-at-the-2024-bio-international-convention/ 2024-05-18T05:55:36+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/MAIA-Biotechnology-Set-to-Showcase-at-the-2024-BIO-International-Convention.webp https://thepharmadata.com/unraveling-anktivas-triangle-offense-exploring-with-dr-patrick-soon-shiong-and-dr-ashish-kamat-on-urotoday-podcast/ 2024-05-18T05:44:09+00:00 https://thepharmadata.com/nadclinic-and-bontac-bio-engineering-form-strategic-partnership-to-advance-global-wellness-with-nad/ 2024-05-18T05:37:28+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/NADclinic-and-Bontac-Bio-Engineering-Form-Strategic-Partnership-to-Advance-Global-Wellness-with-NAD.webp https://thepharmadata.com/report-on-reproductive-hormones-and-proteins-testing-markets-2015-2024-2033/ 2024-05-18T05:32:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Report-on-Reproductive-Hormones-and-Proteins-Testing-Markets-2015-2024-2033.webp https://thepharmadata.com/marinus-pharmaceuticals-unveils-significant-developments-for-tuberous-sclerosis-complex-program/ 2024-05-18T05:28:09+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Marinus-Pharmaceuticals-Unveils-Significant-Developments-for-Tuberous-Sclerosis-Complex-Program.webp https://thepharmadata.com/azitra-inc-reveals-promising-preclinical-results-for-atr-04-at-society-of-investigative-dermatology-annual-meeting/ 2024-05-18T05:24:26+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Azitra-Inc.-Reveals-Promising-Preclinical-Results-for-ATR-04-at-Society-of-Investigative-Dermatology-Annual-Meeting.webp https://thepharmadata.com/who-revises-list-of-drug-resistant-bacteria-posing-greatest-threat-to-human-health/ 2024-05-18T05:14:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/WHO-Revises-List-of-Drug-Resistant-Bacteria-Posing-Greatest-Threat-to-Human-Health.webp https://thepharmadata.com/biontech-se-shareholders-approve-all-proposals-at-2024-annual-general-meeting/ 2024-05-18T05:05:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/BioNTech-SE-Shareholders-Approve-All-Proposals-at-2024-Annual-General-Meeting.webp https://thepharmadata.com/abbvie-showcases-new-data-supporting-premier-gastroenterology-portfolio-at-2024-digestive-disease-week/ 2024-05-18T04:51:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AbbVie-Showcases-New-Data-Supporting-Premier-Gastroenterology-Portfolio-at-2024-Digestive-Disease-Week.webp https://thepharmadata.com/understanding-the-difference-between-ibs-and-ibd/ 2024-05-18T04:43:57+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Understanding-the-Difference-Between-IBS-and-IBD.webp https://thepharmadata.com/weekly-insulin-efsitora-alfa-matches-daily-insulin-in-a1c-reduction-and-safety/ 2024-05-18T04:30:49+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Weekly-Insulin-Efsitora-Alfa-Matches-Daily-Insulin-in-A1C-Reduction-and-Safety.webp https://thepharmadata.com/nucleai-names-vikas-ahuja-as-vp-of-strategic-partnerships-driving-diagnostic-deployment-and-scale-up/ 2024-05-16T12:09:43+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Nucleai-Names-Vikas-Ahuja-as-VP-of-Strategic-Partnerships-Driving-Diagnostic-Deployment-and-Scale-Up.webp https://thepharmadata.com/accentures-investment-in-turbine-to-boost-ai-powered-cell-simulations-for-biopharma-rd/ 2024-05-16T12:03:46+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Accentures-Investment-in-Turbine-to-Boost-AI-Powered-Cell-Simulations-for-Biopharma-RD.webp https://thepharmadata.com/encouraging-phase-ib-findings-from-genentech-on-ct-388-a-dual-glp-1-gip-receptor-agonist-in-individuals-battling-obesity/ 2024-05-16T11:53:32+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Encouraging-Phase-Ib-Findings-from-Genentech-on-CT-388-a-Dual-GLP-1GIP-Receptor-Agonist-in-Individuals-Battling-Obesity.webp https://thepharmadata.com/sunlink-health-systems-inc-reveals-performance-for-fiscal-q3-2024/ 2024-05-16T11:49:05+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/SunLink-Health-Systems-Inc.-Reveals-Performance-for-Fiscal-Q3-2024.webp https://thepharmadata.com/omniab-showcases-xploration-high-throughput-single-b-cell-screening-data-at-20th-annual-pegs-boston-summit/ 2024-05-16T11:45:21+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/OmniAb-Showcases-xPloration%C2%AE-High-Throughput-Single-B-cell-Screening-Data-at-20th-Annual-PEGS-Boston-Summit.webp https://thepharmadata.com/engene-elects-paul-hastings-and-wouter-joustra-to-its-board-of-directors/ 2024-05-16T11:41:16+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/enGene-Elects-Paul-Hastings-and-Wouter-Joustra-to-its-Board-of-Directors.webp https://thepharmadata.com/omeros-corporation-reports-first-quarter-2024-financial-results/ 2024-05-16T11:36:43+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Omeros-Corporation-Reports-First-Quarter-2024-Financial-Results.webp https://thepharmadata.com/gate-neurosciences-to-present-new-synaptic-function-molecule-research-at-2024-ascp-annual-meeting/ 2024-05-16T11:32:57+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Gate-Neurosciences-to-Present-New-Synaptic-Function-Molecule-Research-at-2024-ASCP-Annual-Meeting.webp https://thepharmadata.com/ucsf-in-collaboration-with-nutcracker-therapeutics-unveils-groundbreaking-prostate-cancer-data-at-aai-2024/ 2024-05-16T11:27:54+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/UCSF-in-Collaboration-with-Nutcracker-Therapeutics-Unveils-Groundbreaking-Prostate-Cancer-Data-at-AAI-2024.webp https://thepharmadata.com/vbi-vaccines-reports-first-quarter-2024-financial-results/ 2024-05-16T11:24:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/VBI-Vaccines-Reports-First-Quarter-2024-Financial-Results.webp https://thepharmadata.com/novo-nordisks-mim8-shows-superior-bleeding-reduction-in-hemophilia-a-frontier-2-trial/ 2024-05-15T11:06:17+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Novo-Nordisks-Mim8-Shows-Superior-Bleeding-Reduction-in-Hemophilia-A-Frontier-2-Trial.webp https://thepharmadata.com/quarterly-update-legend-biotechs-performance-and-recent-achievements-in-q1-2024/ 2024-05-14T11:56:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Q1-2024-Qualitative-Report-Performance-Aligns-with-Full-Year-2024-Projections-1.webp https://thepharmadata.com/incytes-plans-to-repurchase-up-to-2-0-billion-worth-of-its-common-stock/ 2024-05-14T11:49:47+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Incytes-Plans-to-Repurchase-Up-to-2.0-Billion-Worth-of-Its-Common-Stock.webp https://thepharmadata.com/fycompa-approved-in-china-as-adjunctive-therapy-for-primary-generalized-tonic-clonic-seizures/ 2024-05-14T11:41:51+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Fycompa%C2%AE-Approved-in-China-as-Adjunctive-Therapy-for-Primary-Generalized-Tonic-Clonic-Seizures.webp https://thepharmadata.com/zilucoplan-shows-significant-fatigue-improvement-in-gmg-journal-of-neurology-study/ 2024-05-14T11:37:50+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Zilucoplan-Shows-Significant-Fatigue-Improvement-in-gMG-Journal-of-Neurology-Study.webp https://thepharmadata.com/fda-approves-baxters-clinolipid-for-neonatal-and-pediatric-use/ 2024-05-14T11:32:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/FDA-Approves-Baxters-Clinolipid-for-Neonatal-and-Pediatric-Use.webp https://thepharmadata.com/astellas-highlights-breakthroughs-in-oncology-at-2024-asco-annual-meeting/ 2024-05-14T11:28:23+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Astellas-Highlights-Breakthroughs-in-Oncology-at-2024-ASCO-Annual-Meeting.webp https://thepharmadata.com/q1-2024-qualitative-report-performance-aligns-with-full-year-2024-projections/ 2024-05-14T11:23:42+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Q1-2024-Qualitative-Report-Performance-Aligns-with-Full-Year-2024-Projections.webp https://thepharmadata.com/first-quarter-performance-as-expected/ 2024-05-14T11:20:04+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/First-quarter-performance-as-expected-1.webp https://thepharmadata.com/ac-immune-and-takeda-enter-exclusive-license-agreement-for-amyloid-beta-immunotherapy-in-alzheimers-disease/ 2024-05-14T11:13:25+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AC-Immune-and-Takeda-Enter-Exclusive-License-Agreement-for-Amyloid-Beta-Immunotherapy-in-Alzheimers-Disease.webp https://thepharmadata.com/sanofi-boosts-biomanufacturing-investment-by-e1b-in-france/ 2024-05-14T11:09:13+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Sanofi-Boosts-Biomanufacturing-Investment-by-E1B-in-France.webp https://thepharmadata.com/abbvie-and-gilgamesh-partner-to-develop-next-gen-psychiatric-therapies/ 2024-05-14T11:02:34+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AbbVie-and-Gilgamesh-Partner-to-Develop-Next-Gen-Psychiatric-Therapies.webp https://thepharmadata.com/global-analysis-rise-in-protein-drug-use-in-hematology-and-oncology-boosts-market-outlook-2023-2028/ 2024-05-11T06:24:54+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Global-Analysis-Rise-in-Protein-Drug-Use-in-Hematology-and-Oncology-Boosts-Market-Outlook-2023-2028.webp https://thepharmadata.com/be-biopharma-unveils-promising-preclinical-data-on-novel-b-cell-treatment-for-hypophosphatasia/ 2024-05-11T06:08:01+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Be-Biopharma-Unveils-Promising-Preclinical-Data-on-Novel-B-Cell-Treatment-for-Hypophosphatasia-1.webp https://thepharmadata.com/gossamer-bio-reveals-inducement-grant-compliant-with-nasdaq-listing-rule-5635c4/ 2024-05-11T06:00:26+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Gossamer-Bio-Reveals-Inducement-Grant-Compliant-with-Nasdaq-Listing-Rule-5635c4.webp https://thepharmadata.com/financial-performance-update-revelation-biosciences-inc-for-q1-2024/ 2024-05-11T05:56:12+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Financial-Performance-Update-Revelation-Biosciences-Inc.-for-Q1-2024.webp https://thepharmadata.com/evolus-discloses-inducement-grants-in-accordance-with-nasdaq-listing-rule-5635c4/ 2024-05-11T05:51:39+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Evolus-Discloses-Inducement-Grants-in-Accordance-with-Nasdaq-Listing-Rule-5635c4.webp https://thepharmadata.com/mirum-pharmaceuticals-announces-inducement-grants-in-accordance-with-nasdaq-listing-rule-5635c4/ 2024-05-11T05:43:35+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Mirum-Pharmaceuticals-Announces-Inducement-Grants-in-Accordance-with-Nasdaq-Listing-Rule-5635c4.webp https://thepharmadata.com/progress-on-proposed-pandemic-agreement-ahead-of-world-health-assembly/ 2024-05-11T05:23:56+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Progress-on-Proposed-Pandemic-Agreement-Ahead-of-World-Health-Assembly.webp https://thepharmadata.com/neurocrine-biosciences-unveils-cahtalyst-adult-study-findings-at-aace-2024/ 2024-05-11T05:18:15+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Neurocrine-Biosciences-Unveils-CAHtalyst%E2%84%A2-Adult-Study-Findings-at-AACE-2024.webp https://thepharmadata.com/viatriss-first-quarter-2024-financial-performance-shows-strength-reaffirms-2024-financial-outlook/ 2024-05-11T05:08:55+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Viatriss-First-Quarter-2024-Financial-Performance-Shows-Strength-Reaffirms-2024-Financial-Outlook.webp https://thepharmadata.com/shionogi-co-ltd-and-maze-therapeutics-inc-strike-exclusive-global-licensing-deal-for-mze001-a-promising-new-treatment-for-pompe-disease/ 2024-05-11T05:04:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Shionogi-Co.-Ltd.-and-Maze-Therapeutics-Inc.-Strike-Exclusive-Global-Licensing-Deal-for-MZE001-a-Promising-New-Treatment-for-Pompe-Disease.webp https://thepharmadata.com/argenx-unveils-financial-performance-for-q1-2024-along-with-business-update/ 2024-05-11T04:53:05+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/argenx-Unveils-Financial-Performance-for-Q1-2024-Along-with-Business-Update.webp https://thepharmadata.com/survey-by-cvs-health-reveals-escalating-concerns-in-mental-health/ 2024-05-11T04:44:54+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Survey-by-CVS-Health%C2%AE-Reveals-Escalating-Concerns-in-Mental-Health.webp https://thepharmadata.com/bristol-myers-squibb-releases-latest-findings-from-phase-3-checkmate-73l-trial/ 2024-05-11T04:32:55+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Bristol-Myers-Squibb-Releases-Latest-Findings-from-Phase-3-CheckMate-73L-Trial.webp https://thepharmadata.com/sanofi-and-novavax-forge-co-exclusive-licensing-deal-to-co-market-covid-19-vaccine-and-innovate-flu-covid-19-combination-vaccines/ 2024-05-11T04:20:15+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Sanofi-and-Novavax-Forge-Co-Exclusive-Licensing-Deal-to-Co-Market-COVID-19-Vaccine-and-Innovate.webp https://thepharmadata.com/keytruda-trial-progress-for-endometrial-cancer-treatment/ 2024-05-09T11:16:41+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Keytruda-Trial-Progress-for-Endometrial-Cancer-Treatment.webp https://thepharmadata.com/enhancing-knee-replacement-surgery-through-robot-assisted-personalization/ 2024-05-09T11:12:40+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Enhancing-Knee-Replacement-Surgery-Through-Robot-Assisted-Personalization.webp https://thepharmadata.com/partnership-announcement-new-malaria-prevention-drug-collaboration-with-nagasaki-university-national-institute-of-infectious-diseases-and-mmv-backed-by-ghit-fund/ 2024-05-09T11:05:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Partnership-Announcement-New-Malaria-Prevention-Drug-Collaboration-with-Nagasaki-University.webp https://thepharmadata.com/beigene-unveils-q1-2024-financial-performance-and-business-developments/ 2024-05-09T11:00:54+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/BeiGene-Unveils-Q1-2024-Financial-Performance-and-Business-Developments.webp https://thepharmadata.com/jeffrey-kindler-and-alfonso-zulueta-appointed-as-independent-directors-to-lupins-board/ 2024-05-09T10:45:54+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Jeffrey-Kindler-and-Alfonso-Zulueta-Appointed-as-Independent-Directors-to-Lupins-Board.webp https://thepharmadata.com/crispr-therapeutics-business-update-and-first-quarter-2024-financial-report/ 2024-05-09T10:40:19+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/CRISPR-Therapeutics-Business-Update-and-First-Quarter-2024-Financial-Report.webp https://thepharmadata.com/revolution-medicines-unveils-q1-2024-financial-report-and-corporate-advancements-update/ 2024-05-09T10:30:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Revolution-Medicines-Unveils-Q1-2024-Financial-Report-and-Corporate-Advancements-Update.webp https://thepharmadata.com/vertex-unveils-financial-performance-for-q1-2024/ 2024-05-07T04:29:55+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Vertex-Unveils-Financial-Performance-for-Q1-2024.webp https://thepharmadata.com/astrazeneca-finalizes-equity-investment-deal-with-cellectis/ 2024-05-07T04:22:10+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AstraZeneca-Finalizes-Equity-Investment-Deal-with-Cellectis.webp https://thepharmadata.com/soleo-health-chosen-as-specialized-pharmacy-partner-for-ryplazim-in-treating-plasminogen-deficiency-type-1-plgd-1/ 2024-05-06T11:04:56+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Soleo-Health-Chosen-as-Specialized-Pharmacy-Partner-for-RYPLAZIM%C2%AE-in-Treating-Plasminogen-Deficiency-Type-1-PLGD-1.webp https://thepharmadata.com/glycomimetics-reveals-findings-from-crucial-phase-3-trial-of-uproleselan-in-relapsed-refractory-acute-myeloid-leukemia-aml/ 2024-05-06T10:57:02+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/GlycoMimetics-Reveals-Findings-from-Crucial-Phase-3-Trial-of-Uproleselan-in-RelapsedRefractory-Acute-Myeloid-Leukemia-AML.webp https://thepharmadata.com/oregon-therapeutics-lantern-pharma-team-up-to-advance-novel-cancer-drug-xce853-with-ai/ 2024-05-06T10:52:27+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Oregon-Therapeutics-Lantern-Pharma-Team-Up-to-Advance-Novel-Cancer-Drug-XCE853-with-AI.webp https://thepharmadata.com/kindeva-drug-delivery-expands-manufacturing-capabilities-for-eco-friendly-inhalers-at-uk-facility/ 2024-05-06T10:47:44+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Kindeva-Drug-Delivery-Expands-Production-Capacity-for-Eco-Friendly-Inhalers-at-UK-Facility-1.webp https://thepharmadata.com/jelmyto-shows-impressive-86-recurrence-free-survival-rfs-at-24-months-across-varied-patient-profiles-insights-from-aua-2024-retrospective-analysis/ 2024-05-06T04:37:35+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/JELMYTO%C2%AE-Shows-Impressive-86-Recurrence-Free-Survival-RFS-at-24-Months-Across-Varied-Patient-Profiles-Insights-from-AUA-2024-Retrospective-Analysis.webp https://thepharmadata.com/exploring-new-frontiers-in-neuroscience-with-ge-healthcares-signa-magnus/ 2024-05-06T04:33:29+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Exploring-New-Frontiers-in-Neuroscience-with-GE-HealthCares-SIGNA-MAGNUS.webp https://thepharmadata.com/genmab-announces-financial-results-for-the-first-quarter-of-2024/ 2024-05-04T05:37:27+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Genmab-Announces-Financial-Results-for-the-First-Quarter-of-2024-scaled.webp https://thepharmadata.com/astellas-and-poseida-therapeutics-collaborate-to-advance-innovative-allogeneic-cell-therapies-for-cancer-treatment/ 2024-05-04T05:32:52+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Astellas-and-Poseida-Therapeutics-Collaborate-to-Advance-Innovative-Allogeneic-Cell-Therapies-for-Cancer-Treatment.webp https://thepharmadata.com/4-ideas-for-honoring-teachers-during-teacher-appreciation-week-may-6-10/ 2024-05-04T05:28:30+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/4-Ideas-for-Honoring-Teachers-During-Teacher-Appreciation-Week-May-6-10.webp https://thepharmadata.com/amgen-announces-financial-performance-for-q1-2024/ 2024-05-04T05:22:48+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Amgen-Announces-Financial-Performance-for-Q1-2024.webp https://thepharmadata.com/alnylam-pharmaceuticals-releases-q1-2024-financial-results-and-highlights-recent-achievements/ 2024-05-04T05:15:13+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Alnylam-Pharmaceuticals-Releases-Q1-2024-Financial-Results-and-Highlights-Recent-Achievements.webp https://thepharmadata.com/moderna-unveils-financial-performance-for-q1-2024-and-business-developments/ 2024-05-04T05:09:17+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Moderna-Unveils-Financial-Performance-for-Q1-2024-and-Business-Developments.webp https://thepharmadata.com/biogens-advancements-in-corporate-responsibility-initiatives/ 2024-05-04T05:03:14+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Biogens-Advancements-in-Corporate-Responsibility-Initiatives.webp https://thepharmadata.com/novartis-strikes-deal-to-purchase-mariana-oncology-bolstering-radioligand-therapy-portfolio/ 2024-05-04T04:56:31+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Novartis-Strikes-Deal-to-Purchase-Mariana-Oncology-Bolstering-Radioligand-Therapy-Portfolio.webp https://thepharmadata.com/calquence-combo-shows-significant-progression-free-survival-boost-in-1st-line-mantle-cell-lymphoma-echo-phase-iii-study/ 2024-05-04T04:47:34+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Calquence-Combo-Shows-Significant-Progression-Free-Survival-Boost-in-1st-Line-Mantle-Cell-Lymphoma-ECHO-Phase-III-Study.webp https://thepharmadata.com/novo-nordisks-q1-2024-revenue-surges-up-by-22-in-danish-kroner-24-at-constant-exchange-rates-reaching-dkk-65-3-billion/ 2024-05-04T04:42:20+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Novo-Nordisks-Q1-2024-Revenue-Surges-Up-by-22-in-Danish-Kroner-24-at-Constant-Exchange-Rates-Reaching-DKK-65.3-Billion.webp https://thepharmadata.com/i-lost-the-ability-to-speak-walk-or-sit-a-glimpse-into-a-rare-autoimmune-disease-targeting-muscles/ 2024-05-04T04:37:15+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/I-Lost-the-Ability-to-Speak-Walk-or-Sit-A-Glimpse-into-a-Rare-Autoimmune-Disease-Targeting-Muscles.webp https://thepharmadata.com/wuxi-apptec-surpasses-first-quarter-2024-goals-amid-external-obstacles-sustaining-operational-stability/ 2024-05-02T05:36:12+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/WuXi-AppTec-Surpasses-First-Quarter-2024-Goals-Amid-External-Obstacles-Sustaining-Operational-Stability.webp https://thepharmadata.com/merck-presents-cutting-edge-pharma-and-electronic-materials-production-to-robert-habeck/ 2024-05-02T05:30:23+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Merck-Presents-Cutting-Edge-Pharma-and-Electronic-Materials-Production-to-Robert-Habeck-.webp https://thepharmadata.com/amgen-highlights-new-copd-asthma-and-vasculitis-research-at-ats-2024/ 2024-05-02T05:21:11+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AMGEN-HIGHLIGHTS-NEW-COPD-ASTHMA-AND-VASCULITIS-RESEARCH-AT-ATS-2024.webp https://thepharmadata.com/amgen-announces-webcast-of-2024-first-quarter-financial-results/ 2024-05-02T05:11:57+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AMGEN-ANNOUNCES-WEBCAST-OF-2024-FIRST-QUARTER-FINANCIAL-RESULTS.webp https://thepharmadata.com/fda-fully-approves-tivdak-for-treating-recurrent-or-metastatic-cervical-cancer/ 2024-05-02T05:09:23+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/FDA-Fully-Approves-TIVDAK%C2%AE-for-Treating-Recurrent-or-Metastatic-Cervical-Cancer.webp https://thepharmadata.com/astrazeneca-highlights-ats-2024-research-in-respiratory-and-immune-diseases-emphasizing-pipeline-strength/ 2024-05-02T05:02:13+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AstraZeneca-Highlights-ATS-2024-Research-in-Respiratory-and-Immune-Diseases-Emphasizing-Pipeline-Strength.webp https://thepharmadata.com/chmp-recommends-approval-of-truqap-and-faslodex-in-the-eu-for-advanced-er-positive-breast-cancer-patients/ 2024-05-02T04:53:58+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/CHMP-Recommends-Approval-of-Truqap-and-Faslodex-in-the-EU-for-Advanced-ER-Positive-Breast-Cancer-Patients.webp https://thepharmadata.com/enhertu-shows-promising-results-in-advanced-breast-cancer-study/ 2024-05-02T04:49:14+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Enhertu-Shows-Promising-Results-in-Advanced-Breast-Cancer-Study.webp https://thepharmadata.com/abbvie-bolsters-dedication-to-science-and-innovation-allocates-e150-million-for-state-of-the-art-research-hub-in-germany/ 2024-05-02T04:45:09+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/AbbVie-Bolsters-Dedication-to-Science-and-Innovation-Allocates-E150-Million-for-State-of-the-Art-Research-Hub-in-Germany.webp https://thepharmadata.com/merck-unveils-promising-results-for-v116-advanced-pneumococcal-vaccine-for-adults/ 2024-05-02T04:39:53+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Merck-Unveils-Promising-Results-for-V116-Advanced-Pneumococcal-Vaccine-for-Adults.webp https://thepharmadata.com/insights-revealed-5-key-discoveries-about-bladder-cancer/ 2024-05-02T04:33:16+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Insights-Revealed-5-Key-Discoveries-About-Bladder-Cancer.webp https://thepharmadata.com/lillys-q1-2024-financials-boosts-full-year-revenue-projection-by-2b-highlights-pipeline-momentum/ 2024-05-02T04:28:15+00:00 https://thepharmadata.com/wp-content/uploads/2024/05/Lillys-Q1-2024-Financials-Boosts-Full-Year-Revenue-Projection-by-2B-Highlights-Pipeline-Momentum.webp https://thepharmadata.com/alentis-appoints-alberto-toso-chief-scientific-officer/ 2024-04-29T11:22:21+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Alentis-Appoints-Alberto-Toso-Chief-Scientific-Officer.webp https://thepharmadata.com/rediscovering-the-essence-of-health-and-care/ 2024-04-29T05:19:21+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Rediscovering-the-Essence-of-Health-and-Care.webp https://thepharmadata.com/lilly-advises-shareholders-to-decline-tutanota-llcs-mini-tender-proposal/ 2024-04-29T05:10:43+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Lilly-Advises-Shareholders-to-Decline-Tutanota-LLCs-Mini-Tender-Proposal.webp https://thepharmadata.com/bio-techne-and-novomol-dx-unveil-point-of-care-ocular-biomarker-test/ 2024-04-27T06:27:06+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Bio-Techne-and-NovoMol-DX-Unveil-Point-of-Care-Ocular-Biomarker-Test.webp https://thepharmadata.com/notice-of-revisions-to-dividend-forecasts-dividend-increase/ 2024-04-27T06:23:21+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/Notice-of-Revisions-to-Dividend-Forecasts-Dividend-Increase.webp https://thepharmadata.com/beigene-showcases-worldwide-advancements-in-2023-corporate-responsibility-sustainability-review/ 2024-04-27T06:15:36+00:00 https://thepharmadata.com/wp-content/uploads/2024/04/BeiGene-Showcases-Worldwide-Advancements-in-2023-Corporate-Responsibility-Sustainability-Review.webp